Convulsive Status Epilepticus Not Responding to Initial Benzodiazepine Therapy — Next Clinical Step

When convulsive status epilepticus persists despite initial benzodiazepine treatment, a structured second-therapy phase is required. This protocol covers the escalation step taken when the first-line benzodiazepine approach fails to terminate seizure activity at the expected response point.

Prior treatment — target not reached
Initial therapy with a benzodiazepine — IM midazolam, IV lorazepam, or IV diazepam — did not terminate convulsive status epilepticus by the 20-minute mark. This protocol defines the next step.
Second-therapy approach — partial overview
The second-therapy phase calls for a single intravenous antiseizure agent. Current evidence does not clearly favour one recommended option over the others; an alternative exists when the primary options are unavailable. The specific agents, selection rationale, and full protocol details are in the structured regimen.
Treatment goal: Termination of convulsive status epilepticus, with response apparent by the 40-minute mark.
Instant Access to Structured Evidence-Based Regimens
References
DOI: 10.5698/1535-7597-16.1.48
  • The second-therapy phase should begin when the seizure duration reaches 20 minutes and should conclude by the 40-minute mark when response (or lack of response) to the second therapy should be apparent.
  • Reasonable options include fosphenytoin (level U), valproic acid (level B, one class II study) and levetiracetam (level U).
  • There is no clear evidence that any one of these options is better than the others.
  • Because of adverse events, IV phenobarbital is a reasonable second-therapy alternative (level B, one class II study) if none of the three recommended therapies are available.
View source ↗